CCR7 and cancer: A comparison between mature mo-DCs from CRC and non-small cell lung cancer (NSCLC) patients, and healthy subjects showed, for example that: i) mo-DCs from healthy donors had a more mature phenotype (higher CD83 and CCR7; lower CD14) than DCs from cancer patients; ii) mo-DCs from CRC patients had a more mature phenotype (higher CD83 and CCR7) than mo-DCs from NSCLC patients; and iii) maturation status of DCs correlated positively with the patients’ clinical status [109].